Ultragenyx Announces Submission of New Drug Application to FDA for UX007 (triheptanoin) for Treatment of Long-Chain Fatty Acid Oxidation Disorders
Go back to Ultragenyx Announces Submission of New Drug Application to FDA for UX007 (triheptanoin) for Treatment of Long-Chain Fatty Acid Oxidation Disorders| ULTRAGENYX PHARM (NASDAQ: RARE) | Delayed: 28.60 +1.16 (4.23%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.44 | 52 Week High | $117.12 | |||
| Open | $27.56 | 52 Week Low | $46.52 | |||
| Day High | $28.63 | P/E | N/A | |||
| Day Low | $27.49 | EPS | $-1.97 | |||
| Volume | 608,429 | |||||
